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Abstract: To provide a better understanding of the actions taken within health systems and their
results, this study aims to assess clinicians’ adherence to clinical practice guidelines (CPGs) regarding
recommended treatments in patients with cardiovascular disease in primary care settings, and to
determine the associated factors. We conducted an ambispective cohort study in 21 primary care centres
in 8 Spanish regions. Patients diagnosed with coronary heart disease, stroke and/or peripheral arterial
disease were included. Patients who received the treatment recommended in the European guidelines
on cardiovascular disease prevention (CPG’s adherent group) were compared with patients who did
not (CPG’s non-adherent group). The outcome variables were cardiovascular hospital admissions,
all-cause and cardiovascular mortality during follow-up. Of the 438 participants, 38.6% (n = 169)
received the drug therapies recommended in the guidelines. The factors that increased the likelihood of
good adherence to CPG’s were being diagnosed with hypertension (p = 0.001), dyslipidaemia (p < 0.001)
or diabetes (p = 0.001), and not having a psychiatric disorder (p = 0.005). We found no statistically
significant association between good adherence to CPG’s and lower incidence of events (p = 0.853).
Clinician adherence to guidelines for secondary prevention of cardiovascular disease was low in the
primary care setting.
Keywords: cardiovascular disease; secondary prevention; primary health care; health systems
1. Introduction
Cardiovascular disease (CVD) remains the number one cause of death in the general population [1].
Coronary heart disease and stroke account for more than half of all incidences of CVD [2]. People who
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already have CVD are at the greatest risk of suffering cardiovascular events and death, but effective
secondary prevention may reduce the risk of recurrence and improve chances of survival [3,4].
Evidence-based clinical practice guidelines (CPGs) [5,6] recommend pharmaceutical intervention,
surgical revascularisation and behavioural changes [3]. CVD morbidity and mortality could be greatly
reduced in secondary prevention through more effective behavioural interventions, risk factor control
and optimal use of prophylactic treatments [7], which is why healthcare professionals must make
every effort to correctly implement clinical practice guidelines.
Previous European studies have investigated adherence to clinical guideline treatment
recommendations (EUROASPIRE I-IV [7–9]), showing that although these recommendations are
increasingly applied in secondary prevention, there is still considerable room for improvement. In 2015,
the authors of the EUROASPIRE IV study [9], who obtained data from 7988 heart disease patients
aged under 80 years from 24 European countries, found that most patients did not achieve the
reference standards for secondary prevention despite the correct use of recommended therapies,
because behavioural changes were insufficient. In 2011, another group of researchers conducted
a cross-sectional survey of primary care physicians in Spain to measure awareness and implementation
of the European CPGs on CVD prevention, finding that although most physicians were familiar with
the guidelines, only one third applied them [10].
With the aim of improving patient care in secondary prevention, in 2011 our research team assessed
the efficacy of a comprehensive programme for secondary cardiovascular prevention in primary care
(PREseAP study [11,12]). The programme did not effectively reduce cardiovascular morbidity and
mortality, but it did improve some aspects related to healthy habits. A better understanding of the
actions taken within healthcare systems—specifically in primary care—and their results could help us to
develop solid, evidence-based prevention and care models to address all the difficulties associated with
CVD. The aim of this study was to assess clinicians’ adherence to CPGs with regard to recommended
treatments in patients with cardiovascular disease in the primary care setting; to determine which
factors were associated with good adherence; and to measure the association between these factors and
patient prognosis.
2. Materials and Methods
We conducted an ambispective observational cohort study in the primary care setting, with the
participation of 21 healthcare centres in eight Spanish regions (Catalonia, Castilla y León, Madrid,
the Basque Country, Aragon, the Balearic Islands, Extremadura and the Valencian Community).
Participants were selected from the control group of the PREseAP study [11,12]. We included all
CVD patients who attended primary care consultations between January 2004 and May 2005 and
who met the inclusion criteria. We followed up with them from inclusion until 2009 or until the first
cardiovascular event. The inclusion criteria were: men and women aged between 50 and 85 years;
being diagnosed with coronary heart disease, stroke and/or peripheral arterial disease between
January 2004 and May 2005; possessing a medical history that was included in the electronic health
records; and providing written informed consent. The exclusion criteria were: having a severe or
terminal disease, being bedridden, having an unstable condition (severe heart valve disease, angina less
than 28 days after an acute myocardial infarction, severe ventricular arrhythmias in the previous six
months) due to their difficulties in attending the visits, or having subarachnoid haemorrhage or
cardioembolic stroke due to known heart valve disease. This study was conducted in accordance with
the Declaration of Helsinki and was approved by the institutional ethics committee.
At the end of the follow-up period, we identified the patients who had received the drug therapies
recommended in the European CPGs on cardiovascular disease prevention [13] (CPG’s adherent
group) and compared them with the patients who had not (CPG’s non-adherent group). In patients
with coronary heart disease, recommended drugs included antiplatelet drugs, lipid-lowering drugs,
beta-blockers, angiotensin-converting-enzyme inhibitors (ACE-Is) or angiotensin II receptor blockers
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(ARBs). In patients with stroke or peripheral arterial disease, recommended drugs included antiplatelet
or lipid-lowering drugs [2,13].
Our data source was medical histories from primary care consultations and tertiary referral
hospitals. The outcome variables were cardiovascular hospital admissions (for acute myocardial
infarction, unstable angina, stroke, coronary revascularisation, acute lower limb ischaemia, amputation
following ischaemia, vascular surgery), all-cause mortality and cardiovascular mortality.
We collected the following sociodemographic variables: Age (50 to 59 years, 60 to 69 years, 70 years
and older), sex, marital status (single, married, widowed, separated/divorced), work situation (actively
employed, retired, unemployed, sick leave/incapacitated, other), level of education (no education,
primary education, secondary/tertiary education) and region. We also collected information on
smoking and drinking habits, categorising smoking status as never smokers, current smokers (smoked
within the previous year) and ex-smokers (quit smoking more than one year ago); and defining
heavy drinkers as men having more than 40 g (4 units) of alcohol per day and women having
more than 24 g (2.4 units) per day. Lastly, we collected data regarding patients’ medical history
(cardiovascular disease, diabetes mellitus, hypertension, dyslipidaemia, chronic obstructive pulmonary
disease, kidney failure, psychiatric disorder), physical examination findings (body mass index (BMI),
waist circumference, systolic and diastolic blood pressure), lab results (blood glucose, total cholesterol,
high-density lipoprotein HDL cholesterol, low-density lipoprotein LDL cholesterol, triglycerides,
creatinine), and prescribed drugs (antiplatelet drugs [acetylsalicylic acid, clopidogrel], beta blockers,
ACE-Is, ARBs, anticoagulants, lipid-lowering drugs, other antihypertensive drugs such as diuretics,
calcium channel blockers or alpha blockers).
At the end of the follow-up, we assessed control of risk factors, defining good control of
hypertension as blood pressure below 140/90 mmHg; good control of dyslipidaemia as LDL below
100 mg/dL; good control of diabetes as glycated haemoglobin below 7%, or below 8% in patients
with advanced complications; good control of smoking as being a non-smoker; and good control
of weight as not being obese (BMI > 30 kg/m2), overweight (BMI > 25 kg/m2) or centrally obese
(waist circumference >102 cm in men and >88 cm in women).
Statistical Analysis
We calculated the sample size from the number of participants in the control group of the PREseAP
study (N = 600). Assuming an incidence of cardiovascular events of 18% in the CPG’s adherent group,
and 30% in the CPG’s non-adherent group and accepting a loss due to missing information in 10% of
clinical records, the estimated sample size had to be at least 219 patients in each group (438 patients
total) to detect differences of 12% with a significance level of 0.05% and a statistical power of 80%.
We performed a descriptive analysis of the sample, presenting the data by frequency and
percentage. To measure the association of adherence to CPG’s and non-adherence to CPG’s with
the categorical variables, we used the Chi-square test. To measure the association of adherence to
CPG’s with morbidity and with sex, we calculated odds ratios (OR) and their 95% confidence intervals
(CIs) using logistic regression. To measure the associations between the explanatory variables and
occurrence of cardiovascular events, we used Cox regression models, calculating the hazard ratio (HR)
and its 95% CI and adjusting the analysis for each explanatory variable. We fitted a multivariable Cox
regression model based on the Akaike information criterion (AIC). The level of statistical significance
was set at p < 0.05. For all analyses we used IBM SPSS statistics V23.0 (IBM, Armonk, NY, USA).
3. Results
Of a total of 600 patients in the control group of the PREseAP study, 438 patients met the inclusion
criteria and were included in this study. The remaining patients were excluded due to missing
information or could not be located during the follow-up. Table 1 shows the sociodemographic
characteristics of the 438 study participants, of whom 72.4% (n = 317) were men and 45.4% (n = 199)
were aged 70 years or older. Of all the participants, 38.6% (n = 169) received the drug therapies
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recommended in the European clinical guidelines (CPG’s adherent group) and 61.4% (n = 269) did not
(CPG’s non-adherent group). The bivariable analysis did not show an association between adherence
to CPG’s and patient characteristics (age, sex, education level, marital status). We only found an
association with area of residence, with the lowest adherence to CPG’s in Aragón and the highest
in Madrid.
Table 1. Participants’ sociodemographic characteristics, by clinician adherence to clinical practice
guidelines (CPGs) for secondary prevention of cardiovascular disease.
Characteristic Total, n (%) Non-Adherence toCPGs, n (%)
Adherence to
CPGs, n (%) p Value
1
Total 438 269 (61.4) 169 (38.6)
Sex
man 317 (72.4) 193 (60.9) 124 (39.1)
woman 121 (27.6) 76 (62.8) 45 (37.2) 0.711
Age
50 to 59 years 118 (26.9) 70 (59.3) 48 (40.7)
60 to 69 years 121 (27.6) 75 (62.0) 46 (38.0)
≥70 years 199 (45.4) 124 (62.3) 75 (37.7) 0.860
Marital status
single 19 (4.3) 12 (63.2) 7 (36.8)
married 348 (79.5) 210 (60.3) 138 (39.7)
separated/divorced 10 (2.3) 9 (90.0) 1 (10.0)
widowed 61 (13.9) 38 (62.3) 23 (37.7) 0.301
Work situation
actively employed 67 (15.3) 39 (58.2) 28 (41.8)
retired 261 (59.6) 164 (62.8) 97 (37.2)
other 110 (25.1) 66 (60.0) 44 (40.0) 0.739
Level of education
no education 151 (34.5) 95 (62.9) 56 (37.1)
primary education 178 (40.6) 104 (58.4) 74 (41.6)
secondary/tertiary education 109 (24.9) 70 (64.2) 39 (35.8) 0.555
Region of residence
Catalonia 113 (25.8) 57 (50.4) 56 (49.6)
Castilla y León 78 (17.8) 55 (70.5) 23 (29.5)
Madrid 34 (7.8) 15 (44.1) 19 (55.9)
Basque Country 37 (8.4) 26 (70.3) 11 (29.7)
Aragon 17 (3.9) 15 (88.2) 2 (11.8)
Balearic Islands 72 (16.4) 45 (62.5) 27 (37.5)
Extremadura 27 (6.2) 19 (70.4) 8 (29.6)
Valencian Community 60 (13.7) 37 (61.7) 23 (38.3) 0.005
1 Chi square test of independence.
Table 2 shows the distribution of the types of cardiovascular disease, risk factors, and incidence
of cardiovascular events and cardiovascular mortality among participants. The most common
cardiovascular disease was coronary heart disease (n = 162; 37.0%) and the most common risk
factor was hypertension (n = 294; 67.1%). There were no significant differences in the proportion
of patients who received the drug therapies recommended in the CPGs between groups of patients
according to cardiovascular disease (p = 0.087). Additionally, the proportion of patients who received
the drug therapies recommended in the CPGs was higher in patients with hypertension than in
those without (43.9% vs. 27.8%; p = 0.001); was higher in patients with dyslipidaemia than in those
without (50.8% vs. 24.3%; p < 0.001); was higher in patients with diabetes than in those without
(50.4% vs. 33.7%; p = 0.001); and was higher in patients without psychiatric disorder than in those with
(40.3% vs. 13.8%; p = 0.005). Moreover, we found that 2.3% of patients (n = 10) died during follow-up
and 18.3% (n = 80) were admitted to hospital due to cardiovascular disease, without statistically
significant differences between the CPG’s adherent and CPG’s non-adherent groups.
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Table 2. Distribution of risk factors, type of cardiovascular disease and clinical history, by clinician
adherence to clinical practice guidelines (CPGs) for secondary prevention of cardiovascular disease.
Variable Total, n (%) Non-Adherenceto CPGs, n (%)
Adherence to
CPGs, n (%) p Value
1
Total 438 269 (61.4) 169 (38.6)
Smoking
non-smoker 167 (38.1) 97 (58.1) 70 (41.9)
ex-smoker 201 (45.9) 130 (64.7) 71 (35.3)
smoker 70 (16.0) 42 (60.0) 28 (40.0) 0.418
Heavy drinker
no 405 (92.5) 245 (60.5) 160 (39.5)
yes 33 (7.5) 24 (72.7) 9 (27.3) 0.165
Cardiovascular disease
CHD 162 (37.0) 108 (66.7) 54 (33.3)
stroke 92 (21.0) 47 (51.1) 45 (48.9)
PAD 15 (3.4) 8 (53.3) 7 (46.7)
≥2 combined diseases (not including CHD) 57 (13.0) 32 (56.1) 25 (43.9)
≥2 combined diseases (including CHD) 112 (25.6) 74 (66.1) 38 (33.9) 0.087
Obese/overweight
no 181 (41.3) 115 (63.5) 66 (36.5)
yes 257 (58.7) 154 (59.9) 103 (40.1) 0.444
Hypertension
no 144 (32.9) 104 (72.2) 40 (27.8)
yes 294 (67.1) 165 (56.1) 129 (43.9) 0.001
Dyslipidaemia
no 202 (46.1) 153 (75.7) 49 (24.3)
yes 236 (53.9) 116 (49.2) 120 (50.8) <0.001
Diabetes
no 309 (70.5) 205 (66.3) 104 (33.7)
yes 129 (29.5) 64 (49.6) 65 (50.4) 0.001
Heart failure
no 406 (92.7) 245 (60.3) 161 (39.7)
yes 32 (7.3) 24 (75.0) 8 (25.0) 0.101
COPD
no 405 (92.5) 246 (60.7) 159 (39.3)
yes 33 (7.5) 23 (69.7) 10 (30.3) 0.309
Chronic kidney disease
no 417 (95.2) 260 (62.4) 157 (37.6)
yes 21 (4.8) 9 (42.9) 12 (57.1) 0.073
Psychiatric disorder
no 409 (93.4) 244 (59.7) 165 (40.3)
yes 29 (6.6) 25 (86.2) 4 (13.8) 0.005
Depression
no 238 (54.3) 147 (61.8) 91 (38.2)
yes 196 (44.7) 120 (61.2) 76 (38.8) 0.908
Anxiety
no 288 (65.8) 177 (61.5) 111 (38.5)
yes 147 (33.6) 90 (61.2) 57 (38.8) 0.962
CV mortality
no 428 (97.7) 264 (61.7) 164 (38.3)
yes 10 (2.3) 5 (50.0) 5 (50.0) 0.453
CV hospital admission
no 358 (81.7) 221 (61.7) 137 (38.3)
yes 80 (18.3) 48 (60.0) 32 (40.0) 0.774
1 Chi square test of independence. CHD: coronary heart disease; PAD: peripheral arterial disease; COPD: chronic
obstructive pulmonary disease; CV: cardiovascular.
The most commonly prescribed treatment was antiplatelet drugs, used by 88.4% of patients (n = 387)
(Table 3). And there are significant differences between groups of disease (p = 0.009). Table 4 displays the
association of adherence to CPG’s with morbidity factors and sex. Patients with stroke were more likely to
receive the recommended drug therapies than those with coronary heart disease (p = 0.005). Other factors
that increased the likelihood of adherence to CPG’s were being diagnosed with hypertension (p = 0.040),
dyslipidaemia (p < 0.001) or diabetes (p = 0.025), and not having a psychiatric disorder (p = 0.016) (Table 4).
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Table 3. Distribution of patients who received the recommended drug therapies by therapeutic group
and type of cardiovascular disease.
Therapeutic Group
Cardiovascular Disease
Total
(n = 438)
CHD
(n = 162)
Stroke
(n = 92)
PAD
(n = 15)
≥2 Diseases (Not
Including CHD)
(n = 57)
≥2 Diseases
(Including CHD)
(n = 112)
p Value 1
n (%) n (%) n (%) n (%) n (%) n (%)
Anti-platelet drugs 387 (88.4) 155 (95.7) 75 (81.5) 13 (86.7) 48 (84.2) 96 (85.7) 0.009
Lipid-lowering drugs 298 (68.0) 125 (77.2) 47 (51.1) 7 (46.7) 34 (59.6) 85 (75.9) <0.001
Beta-blockers 2 187 (68.2) 117 (72.2) 70 (62.5) 0.089
ACE-Is/ARBs 2 106 (38.7) 63 (38.9) 43 (38.4) 0.934
1 Chi square test of independence. 2 This percentage was calculated with respect to the total of patients with CHD
and ≥2 combined diseases including CHD (n = 274). CHD: coronary heart disease; PAD: peripheral arterial disease;
ACE-Is: angiotensin-converting-enzyme inhibitors; ARBs: Angiotensin II receptor blockers.
Table 4. Association between adherence to European clinical practice guidelines (CPGs) for preventing
cardiovascular disease and sociodemographic and morbidity factors.
Factors OR 1 95% CI p Value
Age 0.99 0.97, 1.02 0.678
Sex
man 1
woman 1.44 0.88, 2.34 0.146
Cardiovascular disease
CHD 1
stroke 2.25 1.28, 4.00 0.005
PAD 1.23 0.39, 3.85 0.725
≥2 combined diseases (not including CHD) 1.48 0.75, 2.91 0.256
≥2 combined diseases (including CHD) 0.84 0.48, 1.47 0.538
Hypertension
no 1
yes 1.66 1.02, 2.68 0.040
Dyslipidaemia
no 1
yes 3.28 2.09, 5.16 <0.001
Diabetes
no 1
yes 1.69 1.07, 2.69 0.025
Psychiatric disorder
yes 1
no 4.00 1.30, 12.34 0.016
1 age and sex-adjusted odds ratio. CHD: coronary heart disease; PAD: peripheral arterial disease; 95% CI:
95% confidence interval.
Table 5 shows the association of prognosis, measured by incidence of cardiovascular events
(hospital admission or death) with adherence to CPG’s and other factors. We found no statistically
significant association between adherence to CPG’s and lower incidence of events (p = 0.853). Prognosis
was worse in patients aged over 70 years compared with those aged 60 to 69 years (p = 0.008), in patients
who were incapacitated or on sick leave compared with those who were actively employed (p = 0.006),
and in patients with diabetes (p = 0.014) or depression (p = 0.013).
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Table 5. This Association between prognosis, measured by the incidence of cardiovascular events
(cardiovascular hospital admission or death), and adherence to European clinical practice guidelines
(CPGs) and other factors during follow-up.
Factors HR 1 95% CI p Value
Age
60–69 years 1
≤59 years 1.26 0.56, 2.84 0.576
≥70 years 2.21 1.23, 3.96 0.008
Work
actively employed 1
unemployed 2.72 0.52, 14.26 0.236
sick leave/incapacitated 4.22 1.52, 11.66 0.006
retired 1.91 0.61, 6.00 0.266
other 2.36 0.74,7.55 0.149
Recommended drugs
yes 1
no 0.96 0.62, 1.48 0.853
Diabetes
no 1
yes 1.72 1.12, 2.65 0.014
Depression
no 1
yes 1.75 1.13, 2.80 0.013
1 age and sex-adjusted hazard ratio. HR: hazard ratio; 95% CI: 95% confidence interval.
Table 6 shows the association between adherence to guidelines and control of the main cardiovascular
risk factors. Prescription of the recommended drugs was associated with good control of LDL cholesterol
(p = 0.028), but not with good control of hypertension, blood glucose, weight or smoking.
Table 6. Control of main cardiovascular risk factors, by clinician adherence to clinical practice guidelines
(CPGs) for secondary prevention of cardiovascular disease.
Control of CVR Factors Total, n (%) Non-Adherence toCPGs, n (%)
Adherence to
CPGs, n (%) p Value
1
Hypertension
SBP < 140 and DBP < 90 172 (43.1) 117 (68.0) 55 (32.0)
SBP ≥ 140 or DBP ≥ 90 227 (56.9) 133 (58.6) 94 (41.4) 0.054
LDL cholesterol
<100 172 (46.0) 95 (55.2) 77 (44.8)
≥100 202 (54.0) 134 (66.3) 68 (33.7) 0.028
HDL cholesterol
women ≥ 50; men ≥ 40 204 (53.4) 134 (65.7) 70 (34.3)
women < 50; men < 40 178 (46.6) 102 (57.3) 76 (43.7) 0.093
HbA1c (in diabetics)
<7 90 (74.4) 46 (51.1) 44 (48.9)
7–8 18 (14.9) 9 (50.0) 9 (50.0)
>8 13 (10.7) 5 (38.5) 8 (61.5) 0.695
Obesity
BMI < 30 247 (62.8) 157 (63.6) 90 (36.4)
BMI ≥ 30 146 (37.2) 87 (59.6) 59 (40.4) 0.433
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Table 6. Cont.
Control of CVR Factors Total, n (%) Non-Adherence toCPGs, n (%)
Adherence to
CPGs, n (%) p Value
1
Waist circumference
women < 88; men < 102 69 (17.8) 47 (68.1) 22 (31.9)
women ≥ 88; men ≥ 102 318 (82.2) 196 (61.6) 122 (38.4) 0.313
Smoking
non-smoker 167 (38.1) 97 (58.1) 70 (41.9)
ex-smoker 201 (45.9) 130 (64.7) 71 (35.3)
smoker 70 (16.0) 42 (60.0) 28 (40.0) 0.418
1 Chi square test of independence. CVR: cardiovascular risk; SBP: systolic blood pressure; DBP: diastolic blood
pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; HbA1c: glycated haemoglobin; BMI: body
mass index.
4. Discussion
In our study, 38.6% of CVD patients treated in the primary care setting received the drug therapies
recommended in the European guidelines on cardiovascular disease prevention in clinical practice.
We consider this to be a low proportion, given the efficacy of these drugs in secondary prevention [5],
and believe health systems should be aware of this concern. Patients with stroke were more likely to
receive the recommended drugs compared with those who had coronary heart disease or peripheral
arterial disease. The demographic characteristics, with the exception of region of residence, were not
associated with better adherence to CPGs. Having hypertension, dyslipidaemia or diabetes increased
the likelihood of adherence. Prescription of the recommended drugs was not a determining factor
of prognosis in these patients during the study period, but other factors, such as being older than
70 years, being on sick leave or incapacitated, and having diabetes or depression, were statistically
associated with a higher probability of suffering a cardiovascular event. With regard to control of risk
factors, adherence to CPGs was significantly associated with good control of LDL cholesterol only.
Other authors also reported low adherence to clinical practice guidelines regarding to recommended
treatments in patients with other cardiovascular pathologies. Barnett et al. [14] analysed 9570 patients and
found that over a third of patients with atrial fibrillation did not receive the drug therapies recommended
in the CPGs. In addition, they found no association between guideline-concordant care and improved
risk-adjusted outcomes. On the other hand, Komajda et al. [15] assessed physicians’ adherence to
guideline-recommended medications in 6669 patients with heart failure with reduced ejection fraction
through a survey. They found that the global adherence score was good in 23% of patients, moderate
in 55%, and poor in 22%, and good adherence to drug treatment guidelines was associated with better
clinical outcomes during 6-month follow-up.
We did find statistically significant differences (p < 0.001) between the prescription of lipid
lowering drugs in patients with coronary heart disease (77.2%), stroke (51.1%), peripheral arterial
disease (46.7%), with 2 or more disease conditions not including CHD (56.6%) and with 2 or more
disease conditions including CHD (75.9%).This may be because there is less evidence of the benefits of
lipid lowering treatment in patients with stroke or peripheral arterial disease than in patients with
coronary heart disease [16].
In the EUROASPIRE III study [7], conducted from 2006 to 2007, 94.2% of patients with coronary
heart disease were treated with antiplatelet drugs, 90.1% with lipid-lowering drugs, 81.6% with
beta-blockers and 71.5% with ACE-Is or ARBs. In the present study, these proportions were lower
(88.4%, 68.0%, 68.2% and 38.7%, respectively), since other cardiovascular pathologies were included.
The 2015 EUROASPIRE IV study [9] reported that medication use in CVD had continued to increase,
with 94% of patients using antiplatelet drugs, 86% using lipid-lowering drugs, 83% using beta-blockers
and 75% using ACE-Is or ARBs. The authors also found considerable differences in clinical practice
between the participating countries.
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In our study, patients who had received the drug therapies recommended in the CPGs had
a slightly better prognosis, but this association did not reach statistical significance (Table 6). This group
had more pre-existing diseases (hypertension, dyslipidaemia and diabetes) than the group whose
treatment did not adhere to CPGs, probably because healthcare professionals tend to take greater care
when prescribing treatment to patients with cardiovascular risk factors. As a result, the benefits of
the drug therapy may have been “diluted” in these high-risk patients. We would have to conduct
a controlled clinical trial to ensure the CPG’s adherent and CPG’s non-adherent groups did not differ
in important variables such as prevalence of risk factors. However, this would be unethical, given the
proven benefit of prophylactic drugs.
Although the traditional risk factors explain much of the risk of cardiovascular disease,
psychological factors have also been shown to predict an adverse result. The psychological factor most
frequently studied over the last decade is depression [17]. In our study, patients with depression had
a 75% higher cardiovascular risk. During the study period, physicians used Goldberg’s anxiety and
depression scale (GADS) [18], as per usual clinical practice, during consultations. A recent scientific
statement from the American Heart Association recommends that depression be treated as a risk factor
for morbidity and mortality in coronary heart disease, and that patients be routinely screened for this
psychological disorder [19].
Age is clearly associated with prognosis in CVD. Normally elderly patients are more frail and
have more comorbidities than younger patients, and they are also affected by specifically geriatric
conditions. These factors limit treatment options, reduce adherence to treatment and lead to a worse
prognosis [20]. In our patients, half of whom were aged over 70 years, there was no association between
age and being receiving the recommended drug therapies (Table 5) but we did find an association
between older age and poor prognosis (Table 6). Given that the elderly make up a large proportion of
chronic cardiovascular disease sufferers, it would be useful to design studies focusing exclusively on
this age group [21].
The strengths of our study include its retrospective component, which made it cheaper than
a completely prospective study while also enabling us to effectively assess the effect of risk factors on
comorbidities by ensuring proper temporality, enabling an analysis of cause and effect. One limitation
was the low prescription of recommended drug therapies, which meant we had far fewer patients
who received the drug therapies recommended in the CPGs than patients who did not. In addition,
although our patients had high cardiovascular risk, having suffered a previous cardiovascular event
(secondary prevention), our follow-up period may have been too short to assess the association
between recommended drug therapies and prognosis. Follow-up periods in previous studies have
been of similar length, however.
Although data were collected between 2004 and 2009, the current recommendations for secondary
cardiovascular prevention remain unchanged. Thus, this study allows for a better understanding
of associated factors for the implementation of CPGs and may provide key information for health
systems. To ensure that evidence-based guidelines are followed, health systems must adopt strategies
to facilitate adherence to preventive services guidelines. Further efforts are needed to find the best
encouragements to overcome the barriers to implementation.
5. Conclusions
Clinician adherence to European CPGs for secondary prevention of cardiovascular disease was
low in the primary care setting. Having stroke, being diagnosed with hypertension, dyslipidaemia
or diabetes increased the likelihood of receiving the recommended drugs. Adherence to clinical
guidelines improved control of LDL cholesterol but did not significantly improve patient prognosis in
secondary prevention.
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